|
Q2 FY2026
As of Jul 3, 2026
|
Q1 FY2026
As of Apr 3, 2026
|
Q4 FY2025
As of Jan 2, 2026
|
Q3 FY2025
As of Oct 3, 2025
|
Q2 FY2025
As of Jul 4, 2025
|
Q1 FY2025
As of Apr 4, 2025
|
Q4 FY2024
As of Jan 3, 2025
|
Q3 FY2024
As of Sep 27, 2024
|
Q2 FY2024
As of Jun 28, 2024
|
Q1 FY2024
As of Mar 29, 2024
|
Q4 FY2023
As of Dec 29, 2023
|
Q3 FY2023
As of Sep 29, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 30, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jul 1, 2022
|
Q1 FY2022
As of Apr 1, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Oct 1, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Trade receivables, net | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Long-term investments | ||||||||||||||||||||
| Non-current marketable securities | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Deferred tax assets, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Right-of-use assets and other | ||||||||||||||||||||
| Right-of-use assets and other non-current assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued compensation and benefits | ||||||||||||||||||||
| Accrued clinical trial liabilities | ||||||||||||||||||||
| Rebates and fees due to customers | ||||||||||||||||||||
| Accrued collaboration liabilities | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term portion of deferred revenues | ||||||||||||||||||||
| Non-current operating lease liabilities | ||||||||||||||||||||
| Other non-current liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued | ||||||||||||||||||||
| Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 248,885 and 262,483 at June 30, 2026, and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in-capital | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
| Common Stock, Shares, Issued | ||||||||||||||||||||
Loading...
